ALRN Aileron Therapeutics Inc

USD 6.93 1.23 21.596491
Icon

Aileron Therapeutics Inc (ALRN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 6.93

+1.23 (+21.60)%

USD 0.03B

0.16M

USD 9.00(+29.85%)

USD 0.00 (-100.00%)

Icon

ALRN

Aileron Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 6.93
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.03B

USD 0.00 (-100.00%)

USD 6.93

Aileron Therapeutics Inc (ALRN) Stock Forecast

USD 9.00
(+29.85%)

Based on the Aileron Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Aileron Therapeutics Inc is USD 9.00 over the next 12 months. Aileron Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aileron Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Aileron Therapeutics Inc’s stock price was USD 6.93. Aileron Therapeutics Inc’s stock price has changed by +26.02% over the past week, +52.67% over the past month and +409.63% over the last year.

No recent analyst target price found for Aileron Therapeutics Inc
No recent average analyst rating found for Aileron Therapeutics Inc

Company Overview Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinica...Read More

https://www.aileronrx.com

285 Summer Street, Boston, MA, United States, 02210

6

December

USD

USA

Adjusted Closing Price for Aileron Therapeutics Inc (ALRN)

Loading...

Unadjusted Closing Price for Aileron Therapeutics Inc (ALRN)

Loading...

Share Trading Volume for Aileron Therapeutics Inc Shares

Loading...

Compare Performance of Aileron Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALRN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aileron Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing ALRN

Symbol Name ALRN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aileron Therapeutics Inc (ALRN) Stock

Based on ratings from 1 analysts Aileron Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on ALRN's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ALRN is USD 9.00 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 9.

Unfortunately we do not have enough data on ALRN's stock to indicate if its overvalued.

The last closing price of ALRN's stock was USD 6.93.

The most recent market capitalization for ALRN is USD 0.03B.

Based on targets from 1 analysts, the average taret price for ALRN is projected at USD 9.00 over the next 12 months. This means that ALRN's stock price may go up by +29.85% over the next 12 months.

We can't find any ETFs which contains Aileron Therapeutics Inc's stock.

As per our most recent records Aileron Therapeutics Inc has 6 Employees.

Aileron Therapeutics Inc's registered address is 285 Summer Street, Boston, MA, United States, 02210. You can get more information about it from Aileron Therapeutics Inc's website at https://www.aileronrx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...